NEW YORK, Oct 26 (Reuters) - Bristol-Myers Squibb Co reported on Tuesday better-than-expected quarterly earnings, fueled by lower taxes and cost cuts, but revenue disappointed on weak sales of schizophrenia treatment Abilify and costs of U.S. healthcare reform.
